Inovalon Holdings Inc

Inovalon — Q1 2018 Earnings Presentation

34 slides from Inovalon's earnings presentation, May 8, 2018

  1. Slide 1: Q1 2018 Earnings Supplement

    Q1 2018 Earnings Supplement May 8, 2018

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statement

    Cautionary Note Regarding Forward-Looking Statement Certain statements contained in this presentation constitute forward-looking statements within the meaning of, and are intended to be covered by the safe harbor provisions of, Section 27A of the Securities Act of 1933, as amended, and Section 21E o

  3. Slide 3: Contents

    Contents 1.Acquisition of ABILITY Network This presentation serves as a 2.Inovalon ONE™ Platform Capability supplement to the Inovalon announcement on May 8, 2018 Expansion pertaining to first quarter (Q1) of 2018 results and guidance1. 3.Subscription Base Progression, G&A, and Capital Expenditure I

  4. Slide 4: A Powerful Combination

    A Powerful Combination Through the Inovalon ONE™ Platform, Inovalon supports cloud-based, During Q1 of 2018, the Company real-time connectivity, analytics, interventions, and data visualization for announced a definitive agreement to hundreds of the nation’s leading health plans, pharmaceutical acqu

  5. Slide 5: The Inovalon ONE Platform

    Payers Pharma Devices Diagnostics The Inovalon ONE™ Platform + Massive Advanced Intervention Data Data Assets Analytics Toolsets Visualization A vertically integrated cloud-based platform empowering the achievement of real-time value-based care from payers, pharmaceutical companies, device manufactu

  6. Slide 6: Meaningful Benefits to Healthcare and Stockholders

    • Achieves a vertically integrated cloud-based platform that empowers the achievement of real-time, value-based care from Meaningful payers, manufacturers, and diagnostics all the way to the Benefits to patient’s point of care • Expands on the data scale, connectivity, and impact reach of Healthcare

  7. Slide 7: Expanding Connectivity

    Expanding Connectivity The addition of ABILITY’s extensive connectivity with provider facilities and their information systems will enhance CLINICIAN CONNECTIVITY GROWTH Inovalon’s market differentiation, growth Illustrative of addition through combination opportunities, and cost efficiencies. 140,0

  8. Slide 8: Expanding Datasets

    Expanding Datasets 38 2 ® 37 MORE REGISTRY DATASET GROWTH 36 The addition of ABILITY’s extensive 35 34 Illustrative of addition through combination datasets further expands Inovalon’s 33 32 analytical capabilities and market 31 30 differentiation, driving accelerated 29 28 Patient Count Medical Even

  9. Slide 9: Expand Reach & Accelerate Impact

    Expand Reach & Accelerate Impact Together, Inovalon and ABILITY empower real-time insight and impact, expanded reach and value achievement from the payer, pharmaceutical company, device manufacturer, and diagnostic, all the way down to the provider and patient at the point-of-care. 100s Payers, Phar

  10. Slide 10: Sample Revenue Synergy Opportunities

    Exceptional Sample Revenue Synergy Opportunities: Opportunity for • Expanded Ambulatory Provider Value Realization New Product • Efficient Payer & Provider Encounter Facilitation Development • Advanced Post-Acute Care Provider Support The point-of-care presence and the • Integrated Specialty Pharmac

  11. Slide 11: Synergistic Growth Acceleration

    Synergistic Growth Acceleration 1) Infusing Inovalon’s data and analytics into ABILITY’s offerings empowers new products and greater differentiation to expand and accelerate growth in ABILITY’s core client audience. 2) Applying ABILITY’s sales techniques to Inovalon’s Platform capabilities allows th

  12. Slide 12: Contents

    Contents 1.Acquisition of ABILITY Network This presentation serves as a 2.Inovalon ONE™ Platform Capability supplement to the Inovalon announcement on May 8, 2018 Expansion pertaining to first quarter (Q1) of 2018 results and guidance1. 3.Subscription Base Progression, G&A and Capital Expenditure In

  13. Slide 13: ScriptMed Cloud

    ScriptMed™ Cloud Bringing together scale, robustness, cost efficiencies, and advanced analytics, the introduction of ScriptMed™ Cloud, powered by Components of the Inovalon ONE™ Platform, will enable unmatched functionality and financial benefits for the specialty pharmacy marketplace and the patien

  14. Slide 14: ScriptMed Cloud Advanced Capabilities

    • Sophisticated clinical protocols powered by patient-specific data and ScriptMed™ advanced analytics • Extensive connectivity with EHRs, HIEs, payer systems, and provider- Cloud sites to speed necessary data capture and authorization processes • Modular design allowing health plans and provider sys

  15. Slide 15: CDEaaS

    CDEaaS™ Inovalon’s Clinical Data Extraction as a Service (CDEaaS™) leverages the Inovalon ONE™ Platform’s extensive real-time connectivity, datasets, and large-scale compute processing capacity to autonomously identify and aggregate medical record data faster, at lower costs, and with greater qualit

  16. Slide 16: NLPaaS

    NLPaaS™ Inovalon’s Natural Language Processing as a Service (NLPaaS™) leverages the Inovalon ONE™ Platform’s highly adaptive, machine learning capabilities and billions of known medical events to transform unstructured clinical data into highly valuable, structure clinical data and analyzed results

  17. Slide 17: CDEaaS and NLPaaS Benefits and Broad Need

    ™ • Faster: Results come back in minutes to hours, not weeks to CDEaaS months typically required by alternative, labor-based medical & record collection approaches ™ NLPaaS • More Comprehensive Results: Clients often are unaware of where patients’ clinical data actually resides - a problem solved by

  18. Slide 18: Contents

    Contents 1.Acquisition of ABILITY Network This presentation serves as a 2.Inovalon ONE™ Platform Capability supplement to the Inovalon announcement on May 8, 2018 Expansion pertaining to first quarter (Q1) of 2018 results and guidance1. 3.Subscription Base Progression, G&A and Capital Expenditure In

  19. Slide 19: Subscription-Based Progression

    Subscription-Based Progression Inovalon continues to transition its clients to subscription-based platform offerings from legacy solutions. In Q1 2018, Inovalon generated 74% of revenues from subscription-based platform offerings as compared to 68% in Q1 2017. Excluding client ACA withdrawal impact,

  20. Slide 20: Adjusting for Non-comparable G&A

    Adjusting for Non-comparable G&A General and administrative expenses increased $13.6M in Q1 2018 as compared to Q1 2017. The increase was driven by $4.8M in non- comparable items that do not otherwise relate to Inovalon’s ongoing performance, $4.4M in acquired G&A associated with the CCS acquisition

  21. Slide 21: CAPEX Returning Towards Historical Levels

    CAPEX Returning Towards Historical Levels During the period Q3 2016 through Q1 2018, the Company elected to invest more than $40M into incremental development towards the launch of the Inovalon ONE™ Platform. The period of this disproportional investment is now nearly complete and is increasingly be

  22. Slide 22: Contents

    Contents 1.Acquisition of ABILITY Network This presentation serves as a 2.Inovalon ONE™ Platform Capability supplement to the Inovalon announcement on May 8, 2018 Expansion pertaining to first quarter (Q1) of 2018 results and guidance1. 3.Subscription Base Progression, G&A and Capital Expenditure In

  23. Slide 23: Revenue Offering Mix

    Revenue Offering Mix The following guidance, previously provided on March 7, 2018, is being reaffirmed. $568 - $593 $449.4 $437.3 $427.6 ~75% 53% 54% 66% 43% 34% 19% ~13% 12% 15% ~12% 4% 2015 2016 2017 2018G Services Legacy Solutions Subscription-Based Platform Offerings All numbers in millions. INO

  24. Slide 24: Revenue

    Revenue The following guidance, previously provided on March 7, 2018, is being reaffirmed. $568 - $593 2011 – 2018G $449 13% CAGR $437 $428 $362 $300 $296 $240 2011 2012 2013 2014 2015 2016 2017 2018G Note: CAGR calculations undertaken to the mid-point of 2018 Guidance. All numbers in millions. INOV

  25. Slide 25: Adjusted EBITDA

    Adjusted EBITDA The following guidance, previously provided on March 7, 2018, is being reaffirmed. $163 - $174 $152 $134 2011 – 2018G CAGR 17% $108 $109 $100 $72 $58 36% 37% 35% 29% 24% 24% 23% 24% 2011 2012 2013 2014 2015 2016 2017 2018G % of Revenue Note: CAGR calculations undertaken to the mid-po

  26. Slide 26: Cash Flow From Operations

    Cash Flow From Operations The following is newly provided guidance for 2018. $104 - $115 (Non-GAAP) 1 $98 $93 $86 $90 - $100 2011 – 2018G (GAAP) 1 11% CAGR $66 $68 $54 $46 22% 24% 22% 22% 19% ~19% 18% 16% - ~18% 1 2011 2012 2013 2014 2015 2016 2017 2018G 1 % of Revenue Note: CAGR calculations undert

  27. Slide 27: 2018 Revenue Guidance Bridge

    • Net Client Churn expected to be ~5 points in 2018 2018 Revenue • Client decisions to withdraw from ACA markets, unrelated to the efficacy of Inovalon services, is a short-term headwind of ~8 points in 2018, most pronounced in 1H 2018 • Continued transition and expansion of Inovalon ONE™ Platform a

  28. Slide 28: 2018 Adjusted EBITDA Margin Bridge

    • The full gross margin benefit of an increasing mix of higher margin Platform 2018 Adjusted offerings, coupled with continued technology-enabled efficiencies and the ABILITY acquisition, is seen to be partially offset by one-time client ACA withdrawals EBITDA Margin • Efficiencies achieved in overh

  29. Slide 29: Financial Guidance Table

    Financial Guidance Table The Company is reaffirming financial guidance provided on March 7, 2018 except for the impact of interest expense. 2018 interest expense is expected to be $48M to $49M (inclusive of $4M in original issuance discount and debt issuance fee amortization), an increase of $10M to

  30. Slide 30: Appendix

    Appendix INOV Q1 2018 Earnings Supplement (5.8.18) v 1.0.0 30

  31. Slide 31: Reconciliation of Forward-Looking Guidance Adjusted EBITDA

    Reconciliation of Forward-Looking Guidance Adjusted EBITDA Inovalon defines Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) as net income calculated in accordance with GAAP, adjusted for the impact of depreciation and amortization, realized losses on short-t

  32. Slide 32: Reconciliation of Forward-Looking Guidance Non-GAAP Net Income

    Reconciliation of Forward-Looking Guidance Non-GAAP Net Income Inovalon defines Non-GAAP net income as net income calculated in accordance with GAAP, adjusted to exclude tax-affected stock-based compensation expense, acquisition costs, amortization of acquired intangible assets, tax on equity exerci

  33. Slide 33: Reconciliation of Forward-Looking Guidance Non-GAAP Net Cash Provided By Operating Activities

    Reconciliation of Forward-Looking Guidance Non-GAAP Net Cash Provided By Operating Activities Inovalon defines Non-GAAP net cash provided by operating activities as net cash provided by operating activities calculated in accordance with GAAP, adjusted to exclude transaction and intergration acquisit

  34. Slide 34: Healthcare Empowered

    Healthcare Empowered” RA Pye inovalon

Inovalon Holdings — Q1 2018 Earnings Presentation on 6ix